SCHEMBL970666

SCHEMBL970666

CCCc1nc(C)c2c(C)nc3c(OC)cc(OC)cc3n12

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 20/20 0.55
PDE2A O00408 16/20 0.55
PDE11A Q9HCR9 6/20 0.55
PDE5A O76074 5/20 0.55
PDE4A P27815 3/20 0.55
PDE4D Q08499 2/20 0.46
PDE3A Q14432 2/20 0.46
PDE7A Q13946 1/20 0.46
PDE7B Q9NP56 1/20 0.46
PDE6D O43924 1/20 0.41
PDE6A P16499 1/20 0.41
PDE6G P18545 1/20 0.41
PDE6B P35913 1/20 0.41
PDE6C P51160 1/20 0.41
PDE6H Q13956 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12947966 0.87 PDE10A (0.57) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL968400 0.79 PDE10A (0.50) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL969451 0.78 PDE10A (0.60) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL973647 0.75 PDE10A (0.56) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL969355 0.74 PDE10A (0.67) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL12947964 0.74 PDE2A (0.58) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL12948061 0.73 PDE10A (0.60) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL970391 0.72 PDE10A (0.77) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL8042597 0.72 PDE10A (0.49) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL970200 0.72 PDE10A (0.49) PDE10APDE2APDE11APDE5APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US claimed
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A PDE10A 3/4885PDE2A 6/4885PDE11A 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.